Detection of pleiotrophin
The invention relates to a novel method and kit for detecting and measuring pleiotrophin in samples and diagnosing pleiotrophin-positive diseases. The method involves incubating a sample suspected of containing PTN with anti-PTN antibodies and determining the presence of PTN using a sandwich ELISA. Also methods for treating a pleiotrophin-positive disease by administering an anti-PTN antibody or fragment thereof are provided.
1. A method for diagnosis of cancer selected from the group consisting of pancreatic, colon, stomach, melanoma, and breast cancer, comprising the steps of:
(i) contacting a sample from a patient suspected of having cancer selected from the group consisting of pancreatic, colon, stomach, melanoma, and breast cancer with antibodies which recognize pleiotrophin;
(ii) detecting the presence or absence of a complex formed between pleiotrophin in the sample and antibodies specific therefor; and
(iii) comparing the amount of pleiotrophin in said sample to a normal control, wherein an increase in the amount of pleiotrophin in the sample compared to the control indicates the presence of said cancer.
2. A method for evaluating the prognosis of cancer selected from the group consisting of pancreatic, colon, stomach, melanoma, and breast cancer, comprising the following steps:
(i) contacting a sample from a patient suspected of having cancer selected from the group consisting of pancreatic, colon, stomach, melanoma, and breast cancer with antibodies which recognize pleiotrophin;
(ii) detecting the presence or absence of a complex formed between pleiotrophin in the same and antibodies specific therefor; and
(iii) comparing the amount of pleiotrophin in said sample to a normal control, wherein an increase in the amount of pleiotrophin in the sample compared to the control indicates the prognosis of said cancer.
3. A method for monitoring the effectiveness of a therapeutic treatment of cancer selected from the group consisting of pancreatic, colon, stomach, melanoma, and breast cancer, comprising the following steps:
(i) contacting a sample from a patient who has undergone therapeutic treatment of cancer selected from the group consisting of pancreatic, colon, stomach, melanoma, and breast cancer with antibodies which recognized pleiotrophin;
(ii) detecting the level of complexes formed between pleiotrophin and antibodies specific therefor; and
(iii) comparing an amount of post-treatment pleiotrophin levels to an initial pleiotrophin levels prior to treatment, wherein a decrease in post-pleiotrophin levels indicates an effective treatment.
4. The method according to claim 3 , wherein said treatment is selected from the group consisting of surgical treatment, radiation treatment, and chemical treatment.
5. An in vitro method for testing agents or drugs that inhibit or increase pleiotrophin, said method comprising:
(i) administering a drug or agent to cells that express pleiotrophin;
(ii) detecting pleiotrophin using a mouse monoclonal antibody directed against pleiotrophin;
(iii) comparing the amount of pleiotrophin to control cells that did not receive said drug or agent, wherein a decrease in pleiotrophin compared to control indicates a pleiotrophin inhibitory agent or drug and an increase in pleiotrophin compared to control indicates a pleiotrophin stimulatory agent or drug.